Globally, anxiety is one of the most widespread mental pathologies. Despite the accessibility of treatment, a significant portion of patients are not fully freed from symptoms, which indicates the insufficient effectiveness of current therapeutic approaches. New neurochemical research has revealed a significant link: a choline deficiency—a vitally important nutrient for neuronal membrane metabolism and neurotransmitter synthesis—may be a decisive etiological factor in the development of anxiety disorders.
Researchers at the University of California (UC Davis Health) conducted the first large-scale meta-analysis to assess the cerebral concentration of choline-containing compounds (tCho) in patients diagnosed with various anxiety pathologies (GAD—Generalized Anxiety Disorder, panic disorder, social anxiety).
The research, based on 25 independent datasets, used Proton Magnetic Resonance Spectroscopy () to compare brain metabolites between patients with anxiety disorders and healthy control subjects. The results showed that anxiety patients had an average of 8% lower level of tCho in the cerebral cortex. This deficit was most clearly observed in the prefrontal cortex, a region crucial for executive functions, decision-making, and emotional regulation.
Choline compounds, such as glycerophosphocholine and phosphocholine, are biomarkers of cell membrane renewal and phospholipid metabolism. Accordingly, the reduced level of tCho likely indicates structural changes in the neuronal membrane and/or a decrease in choline bioavailability.
Choline is also essential for the formation of acetylcholine—a substance that plays a decisive role in our cognitive abilities and emotional balance. Consequently, choline deficiency may lead to a decline in cognitive functions, which is directly linked to the clinical manifestations of anxiety disorders.
The accuracy of measurement in the study was strictly assessed (the coefficient of variation—COV—was used). Researchers found that other factors (e.g., medications, age, gender, or spectrometer parameters) had little influence on choline levels. This confirms that tCho is a reliable neurometabolic indicator for anxiety disorders.
What Could Be the Cause of Low Choline Levels in the Brain?
According to one hypothesis, prolonged stress and the body’s heightened response (“fight-or-flight” reaction) may increase the demand for choline, leading to its depletion in the central nervous system. At the same time, poor nutrition is a risk factor, as most adults do not consume the recommended daily intake of choline. (Choline is found in large amounts in eggs, meat, and some vegetables.)
In addition, since choline is an essential component in methylation reactions and the process of epigenetic regulation, correcting its levels would facilitate neuroplasticity and the structural and functional reorganization of the brain. This, in turn, would strengthen the nervous system’s regenerative abilities.
The meta-analysis, besides choline, also revealed a small but statistically significant reduction in N-Acetylaspartate (NAA) (an indicator of neuronal “health”) in the cerebral cortex. This result suggests that some neural cell damage may occur alongside anxiety.
Ultimately, the recognition of low choline levels as a hidden etiological factor in anxiety has the potential to change existing diagnostic and therapeutic strategies.
Source: Molecular psychiatry
